Involvement of p53 in gemcitabine mediated cytotoxicity and radiosensitivity in breast cancer cell lines

Gene

Volumn 498, Issue 2, 2012, Pages 300-307

  Salem, Sameer D ^a,b   Abou Tarboush, Faisal M ^b   Saeed, Nadeem M ^a   Al Qadasi, Waheeb D ^a   Farah, M Abul ^b   Al Buhairi, Muneera ^c   Al Harbi, Najla ^c   Alhazza, Ibrahim ^b   Alsbeih, Ghazi ^c  

^a SANA A UNIVERSITY   (Yemen)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

Breast cancer; Cytotoxicity; DNA double strand breaks; Gemcitabine; p53; Radiosensitivity

Indexed keywords

GEMCITABINE; PROTEIN P53;

ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER CELL CULTURE; CELL CYCLE; CELL STRAIN MCF 7; CLONOGENIC ASSAY; CONTROLLED STUDY; CYTOTOXICITY; DNA REPAIR; DOUBLE STRANDED DNA BREAK; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; MUTANT; PRIORITY JOURNAL; PULSED FIELD GEL ELECTROPHORESIS; RADIOSENSITIVITY; RADIOSENSITIZATION; WILD TYPE;

ANTIMETABOLITES, ANTINEOPLASTIC; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; DEOXYCYTIDINE; DNA BREAKS, DOUBLE-STRANDED; DNA REPAIR; ELECTROPHORESIS, GEL, PULSED-FIELD; EPITHELIAL CELLS; FEMALE; HUMANS; MUTATION; RADIATION-SENSITIZING AGENTS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84858753779     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2012.01.099     Document Type: Article

References (50)

1. Bernhard J., Dietrich D., Scheithauer W., Gerber D., Bodoky G., Ruhstaller T., Glimelius B., Bajetta E., Schuller J., Saletti P., Bauer J., Figer A., Pestalozzi B.C., Kohne C.H., Mingrone W., Stemmer S.M., Tamas K., Kornek G.V., Koeberle D., Herrmann R. Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial-SAKK 44/00-CECOG/PAN.1.3.001. J. Clin. Oncol. 2008, 26:3695-3701.
2. Burris H.A., Moore M.J., Andersen J., Green M.R., Rothenberg M.L., Modiano M.R., Cripps M.C., Portenoy R.K., Storniolo A.M., Tarassoff P., Nelson R., Dorr F.A., Stephens C.D., Von Hoff D.D. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 1997, 15:2403-2413.
3. Canman C.E., Kastan M.B. Role of p53 in apoptosis. Adv. Pharmacol. 1997, 41:429-460.
4. Cascalló M., Calbó J., Gelpí J.L., Mazo A. Modulation of drug cytotoxicity by reintroduction of wild-type p53 gene (Ad5CMV-p53) in human pancreatic cancer. Cancer Gene Ther. 2000, 7:545-556.
5. Cascalló M., Calbó J., Capellà G., Fillat C., Pastor-Anglada M., Mazo A. Enhancement of gemcitabine-induced apoptosis by restoration of p53 function in human pancreatic tumors. Oncology 2005, 68:179-189.
6. Chen M., Hough A., Lawrence T. The role of p53 in gemcitabine-mediated cytotoxicity and radiosensitization. Cancer Chemother. Pharmacol. 2000, 45:369-374.
7. Chew H.K., Doroshow J.H., Frankel P., Margolin K.A., Somlo G., Lenz H.J., Gordon M., Zhang W., Yang D., Russell C., Spicer D., Synold T., Bayer R., Hantel A., Stiff P.J., Tetef M.L., Gandara D.R., Albain K.S. Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer. J. Clin. Oncol. 2009, 27:2163-2169.
8. Crino L., Mosconi A.M., Scagliotti G.V., Selvaggi G., Rinaldi M., Della Giulia M., Gridelli C., Calandri C., De Marinis F., Noseda M., Tonato M. Gemcitabine as second-line treatment for relapsing or refractory advanced non-small cell lung cancer: a phase II trial. Semin. Oncol. 1998, 25:23-26.
9. Fan S., El-Deiry W.S., Bae I., Freeman J., Jondle D., Bhatia K., Fornace A.J., Magrath I., Kohn K.W. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res. 1994, 54:5824-5830.
10. Fan S., Smith M.L., Rivet I.I., Duba D., Zhan Q., Kohn K.W., Fornace A.J., O'Connor P.M. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res. 1995, 1555:1649-1654.
11. Fertil B., Dertinger H., Courdi A., Malaise E.P. Mean inactivation dose: a useful concept for intercomparison of human cell survival curves. Radiat. Res. 1984, 99:73-84.
12. Fiscella M., Zhang H., Fan S., Sakaguchi K., Shen S., Mercer W.E., Vande Woude G.F., O'Connor P.M., Appella E. A novel human protein phosphatase that is induced in response to ionizing radiation in a p53-dependent manner. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:6048-6053.
13. Gottlieb T.M., Oren M. p53 in growth control and neoplasia. Biochim. Biophys. Acta 1996, 1287:77-102.
14. Grasso L., Mercer W.E. Pathways of p53-dependent apoptosis. Vitam. Horm. 1997, 53:139-173.
15. Grégoire V., Beauduin M., Bruniaux M., De Coster B., Octave P.M., Scalliet P. Radiosensitization of mouse sarcoma cells by fludarabine (F-ara-A) or gemcitabine (dFdC), two nucleoside analogues, is not mediated by an increased induction or a repair inhibition of DNA double-strand breaks as measured by pulsed-field gel electrophoresis. Int. J. Radiat. Biol. 1998, 73:511-520.
16. Gupta M., Fan S., Zhan Q., Kohn K.W., O'Connor P.M., Pommier Y. Inactivation of p53 increases the cytotoxicity of camptothecin in human colon HCT116 and breast MCF-7 cancer cells. Clin. Cancer Res. 1997, 3:1653-1660.
17. Hartwell L.H., Kastan M.B. Cell cycle control and cancer. Science (Washington DC) 1994, 266:1821-1828.
18. Hawkins D.S., Demers G.W., Galloway D.A. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res. 1996, 56:892-898.
19. Hollstein M., Rice K., Greenblatt M.S., Soussi T., Fuchs R., Sorlie T., Hovig E., Smith-Sorensen B., Montesano R., Harris C.C. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res. 1994, 22:3551-3555.
20. Ko L.J., Prives C. p53: puzzle and paradigm. Genes Dev. 1996, 10:1054-1072.
21. Lane D.P. p53: guardian of genome. Nature 1992, 358:15-16.
22. Latz D., Fleckenstein K., Eble M., Blatter J., Wannenmacher M., Weber K.J. Radiosensitizing potential of gemcitabine (2',2'-difluoro-2'-deoxycytidine) within the cell cycle in vitro. Int. J. Radiat. Oncol. Biol. Phys. 1998, 41:875-882.
23. Lawrence T.S., Chang E.Y., Hahn T.M., Hertel L.W., Shewach D.S. Radiosensitization of pancreatic cancer cells by 2',2'-difluoro-2'-deoxycytidine. Int. J. Radiat. Oncol. Biol. Phys. 1996, 34:867-872.
24. Lawrence T.S., Chang E.Y., Hahn T.M., Shewach D.S. Delayed radiosensitization of human colon carcinoma cells after a brief exposure to 2',2'-difluoro-2'-deoxycytidine (Gemcitabine). Clin. Cancer Res. 1997, 3:777-782.
25. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell 1997, 88:323-331.
26. Lowe S.W., Schmitt E.M., Smith S.W., Osborne B.A., Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993, 362:847-849.
27. Mallya S.M., Sikpi M.O. Requirement for p53 in ionizing-radiation-inhibition of double-strand-break rejoining by human lymphoblasts. Mutat. Res. 1999, 434:119-132.
28. McGinn C.J., Shewach D.S., Lawrence T.S. Radiosensitizing nucleosides. J. Natl. Cancer Inst. 1996, 88:1193-1203.
29. Mcllwrath A.J., Vasey P.A., Ross G.M., Brown R. Cell cycle arrests and radiosensitivity of human tumor cell lines: dependence on wild-type p53 for radiosensitivity. Cancer Res. 1994, 54:3718-3722.
30. Morgan S.E., Kastan M.B. p53 and ATM: cell cycle, cell death, and cancer. Adv. Cancer Res. 1997, 71:1-25.
31. Morgan M.A., Poynter J.N., Maybaum J., Lawrence T.S. The role of Bcl-X(S) in radiation sensitivity. Radiat. Res. 2004, 161:535-539.
32. Morris S.M. A role for p53 in the frequency and mechanism of mutation. Mutat. Res. 2002, 511:45-62.
33. Nemunaitis J., Swisher S.G., Timmons T., Connors D., Mack M., Doerksen L., Weill D., Wait J., Lawrence D.D., Kemp B.L., Fossella F., Glisson B.S., Hong W.K., Khuri F.R., Kurie J.M., Lee J.J., Lee J.S., Nguyen D.M., Nesbitt J.C., Perez-Soler R., Pisters K.M., Putnam J.B., Richli W.R., Shin D.M., Walsh G.L., Merritt J., Roth J. Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. J. Clin. Oncol. 2000, 18:609-622.
34. O'Connor P.M., Jackman J., Bae I., Myers T.G., Fan S., Mutoh M., Scudiero D.A., Monks A., Sausville E.A., Weinstein J.N., Friend S., Fornace A.J., Kohn K.W. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth inhibitory potency of 123 anticancer agents. Cancer Res. 1997, 57:4285-4300.
35. O'Connor P.M., Kohn K.W. A fundamental role for cell cycle regulation in the chemosensitivity of cancer cells?. Semin. Cancer Biol. 1992, 3:409-416.
36. Ostruszka L.J., Shewach D.S. The role of cell cycle progression in radiosensitization by 2',2'-difluoro-2'-deoxycytidine. Cancer Res. 2000, 60:6080-6088.
37. Pacini S., Milano F., Pinzani P., Pazzagli M., Gulisano M., Ruggiero M., Casamassima F. Effects of gemcitabine in normal and transformed human lung cell cultures: cytotoxicity and increase in radiation sensitivity. Tumori 1999, 85:503-507.
38. Pauwels B., Korst A.E., Lardon F., Vermorken J.B. Combined modality therapy of gemcitabine and radiation. Oncologist 2005, 10:34-51.
39. Pauwels B., Vermorken J.B., Wouters A., Ides J., Van Laere S., Lambrechts H.A., Pattyn G.G., Vermeulen K., Meijnders P., Lardon F. The role of apoptotic cell death in the radiosensitising effect of gemcitabine. Br. J. Cancer 2009, 101:628-636.
40. Prives C., Hall P.A. The p53 pathway. J. Pathol. 1999, 187:112-126.
41. Robinson B.W., Shewach D.S. Radiosensitization by gemcitabine in p53 wild-type and mutant MCF-7 breast carcinoma cell lines. Clin. Cancer Res. 2001, 7:2581-2589.
42. Robinson B.W., Im M.M., Ljungman M.M., Praz F., Shewach D.S. Enhanced radiosensitization with gemcitabine in mismatch repair-deficient HCT116 cells. Cancer Res. 2003, 63:6935-6941.
43. Shewach D.S., Lawrence T.S. Antimetabolite radiosensitizers. J. Clin. Oncol. 2007, 25:4043-4050.
44. Shewach D.S., Hahn T.M., Chang E., Hertel L.W., Lawrence T.S. Metabolism of 2',2'-difluoro-2'-deoxycytidine and radiation sensitization of human colon carcinoma cells. Cancer Res. 1994, 54:3218-3223.
45. Veltkamp S.A., Beijnen J.H., Schellens J.H. Prolonged versus standard gemcitabine infusion: translation of molecular pharmacology to new treatment strategy. Oncologist 2008, 13:261-276.
46. Wouters A., Pauwels B., Lambrechts H.A., Pattyn G.G., Ides J., Baay M., Meijnders P., Peeters M., Vermorken J.B., Lardon F. Retention of the in vitro radiosensitizing potential of gemcitabine under anoxic conditions, in p53 wild-type and p53-deficient non-small-cell lung carcinoma cells. Int. J. Radiat. Oncol. Biol. Phys. 2011, 80:558-566.
47. Yang S., Zhang X., Jiang M., Ashamalla H., Rafla S. Unusual radiation response of gemcitabine-treated HeLa cells: reduced and enhanced survival. Cancer Lett. 2002, 187:179-183.
48. Yardley D.A., Burris H.A., Simons L., Spigel D.R., Greco F.A., Barton J.H., Shipley D., Drosick D., Hainsworth J.D. A phase II trial of gemcitabine/carboplatin with or without trastuzumab in the first-line treatment of patients with metastatic breast cancer. Clin. Breast Cancer 2008, 8:425-431.
49. Zatloukal P., Kanitz E., Magyar P., Jassem J., Krzakowski M., Pawlicki M., Petruzelka L., Chovan L., Pesek M., Janko C., Krejcy K. Gemcitabine in locally advanced and metastatic non-small cell lung cancer: the Central European phase II study. Lung Cancer 1998, 22:243-250.
50. Zhan Q., Fan S., Bae I., Guillouf C., Liebermann D.A., O'Connor P.M., Fornace A.J. Induction of bax by genotoxic stress in human cells correlates with normal p53 status and apoptosis. Oncogene 1994, 9:3743-3751.